Strategic Investments to Drive Healthcare Innovation

The Rezk Foundation focuses its investments on high-impact areas in the biopharma industry to address unmet medical needs and create sustainable value in emerging markets. Our approach is centered on three core pillars: Clinical Trial Operational Investments, Licensing Opportunities, and Technology Transfer Initiatives. These areas form the foundation of our mission to accelerate the development and commercialization of innovative therapies.

Our investments are aligned with high-priority therapeutic areas, including:

• Vaccines: High-valency PCV, high-valency HPV, RSV, recombinant shingles, and rotavirus vaccines.

• Blood Products: Immunoglobulins, clotting factors, and innovative genetic blood therapies.

• Genetic Therapies: Enzyme replacement therapies, gene therapies, and treatments for inherited disorders.

• Rare Diseases: Addressing conditions with significant unmet needs, including orphan oncology products and lysosomal storage disorders.

Investing in clinical trials is critical to advancing innovative therapies from development to market. The Rezk Foundation provides operational funding and strategic support to biotechs seeking to validate their products and scale globally.

• Funding Late-Stage Trials: Focused on Phase II and III trials for vaccines, blood products, genetic therapies, and rare disease treatments.

• Streamlining Operations: Providing resources to optimize trial design, recruitment, and site management in emerging markets.

• Regulatory Strategy Integration: Supporting compliance with international standards (e.g., PICS, WHO, FDA) to ensure trial data aligns with global expectations.

• Accelerates Time-to-Market: Efficient trials bring therapies to patients faster.

• Supports Innovation: Enables biotechs to focus on product development without financial constraints.

• Addresses Unmet Needs: Trials conducted in emerging markets generate data specific to regional populations.

Licensing is a powerful tool for expanding the reach of innovative therapies. The Rezk Foundation facilitates in-licensing of cutting-edge products into underserved regions and out-licensing from emerging markets to the global stage.

In-Licensing:

• Bringing innovative therapies like high-valency vaccines and genetic treatments into underserved markets.
• Navigating regulatory pathways to ensure smooth market entry.

Out-Licensing:

• Helping biotechs in emerging markets expand internationally by finding the right global partners.
• Structuring agreements that maximize both reach and profitability.

Negotiation and Structuring:

• Crafting win-win licensing agreements that protect IP while promoting accessibility.

• Expands Market Access: Enables underserved regions to access advanced therapies.

• Drives Global Impact: Scales innovations from emerging markets to reach broader populations.

• Strengthens Partnerships: Builds long-term relationships across the biopharma ecosystem.

Technology transfer is essential for localizing production and ensuring the sustainability of healthcare ecosystems. The Rezk Foundation invests in tech transfer initiatives to help emerging markets build the infrastructure needed for manufacturing and distribution.

Local Production Enablement:

• Facilitating the transfer of manufacturing knowledge and technology to local facilities.
• Supporting infrastructure upgrades to meet GMP standards.

Capacity Building:

• Training local teams to operate production facilities efficiently.
• Building expertise in drug substance (DS) and drug product (DP) production.

Sustainable Ecosystems:

• Encouraging governments and local stakeholders to invest in localized healthcare production.

• Increases Accessibility: Reduces dependency on imports, making therapies more affordable.

• Promotes Independence: Strengthens healthcare sovereignty in emerging markets.

• Drives Long-Term Growth: Creates jobs, boosts local economies, and fosters innovation ecosystems.